Related Experiment Video
Updated: Jan 12, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer:
Evan Y Yu1, Hiroyoshi Suzuki2, Christopher M Pieczonka3
1Fred Hutchinson Cancer Center and University of Washington, Seattle, WA, USA. evanyu@uw.edu.
Background:
DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Subjects/Methods:
This prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily.
Results:
Darolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS.
Conclusions:
These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.
